High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$4.1M
$4,127,328
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
ALKS
S
Alkermes plc.
Gaffin David Joseph
• Officer • EVP, CLO, Alkermes, Inc.
10b5-1 Sell
2026-03-03
$60,532
|
||||||
| ALKS |
Alkermes plc.
|
Officer • EVP, CLO, Alkermes, Inc.
10b5-1 Sell
|
2026-03-03 | $60,532 | S | Form 4 |
|
ALKS
S
Alkermes plc.
Gaffin David Joseph
• Officer • EVP, CLO, Alkermes, Inc.
10b5-1 Sell
2026-03-02
$59,576
|
||||||
| ALKS |
Alkermes plc.
|
Officer • EVP, CLO, Alkermes, Inc.
10b5-1 Sell
|
2026-03-02 | $59,576 | S | Form 4 |
|
ALKS
S
Alkermes plc.
Hopkinson Craig C.
• Officer • EVP R&D, Chief Medical Officer
10b5-1 Sell
2026-03-02
$267,485
|
||||||
| ALKS |
Alkermes plc.
|
Officer • EVP R&D, Chief Medical Officer
10b5-1 Sell
|
2026-03-02 | $267,485 | S | Form 4 |
|
ALKS
S
Alkermes plc.
Nichols Christian Todd
• Officer • SVP, Chief Commercial Officer
10b5-1 Sell
2026-03-02
$180,000
|
||||||
| ALKS |
Alkermes plc.
|
Officer • SVP, Chief Commercial Officer
10b5-1 Sell
|
2026-03-02 | $180,000 | S | Form 4 |
|
ALKS
S
Alkermes plc.
Parisi Samuel Joseph
• Officer • VP, Finance (Interim PAO)
10b5-1 SellΔOwn -47.2%
2026-03-02
$201,808
|
||||||
| ALKS |
Alkermes plc.
|
Officer • VP, Finance (Interim PAO)
10b5-1 SellΔOwn -47.2%
|
2026-03-02 | $201,808 | S | Form 4 |
| ALKS |
Alkermes plc.
|
Director
10b5-1 SellΔOwn -17.6%
|
2026-02-02 | $2,115,673Largex2 | S | Form 4 |
|
ALKS
S
Alkermes plc.
Hopkinson Craig C.
• Officer • EVP R&D, Chief Medical Officer
10b5-1 Sell
2026-02-02
$305,384x2
|
||||||
| ALKS |
Alkermes plc.
|
Officer • EVP R&D, Chief Medical Officer
10b5-1 Sell
|
2026-02-02 | $305,384x2 | S | Form 4 |
|
ALKS
S
Alkermes plc.
Hopkinson Craig C.
• Officer • EVP R&D, Chief Medical Officer
10b5-1 Sell
2026-01-08
$150,005
|
||||||
| ALKS |
Alkermes plc.
|
Officer • EVP R&D, Chief Medical Officer
10b5-1 Sell
|
2026-01-08 | $150,005 | S | Form 4 |
|
ALKS
S
Alkermes plc.
Hopkinson Craig C.
• Officer • EVP R&D, Chief Medical Officer
10b5-1 Sell
2025-12-03
$112,447
|
||||||
| ALKS |
Alkermes plc.
|
Officer • EVP R&D, Chief Medical Officer
10b5-1 Sell
|
2025-12-03 | $112,447 | S | Form 4 |
|
ALKS
S
Alkermes plc.
Hopkinson Craig C.
• Officer • EVP R&D, Chief Medical Officer
10b5-1 Sell
2025-12-01
$117,200
|
||||||
| ALKS |
Alkermes plc.
|
Officer • EVP R&D, Chief Medical Officer
10b5-1 Sell
|
2025-12-01 | $117,200 | S | Form 4 |
|
ALKS
S
Alkermes plc.
Hopkinson Craig C.
• Officer • EVP R&D, Chief Medical Officer
10b5-1 SellΔOwn -11.4%
2025-11-03
$273,442
|
||||||
| ALKS |
Alkermes plc.
|
Officer • EVP R&D, Chief Medical Officer
10b5-1 SellΔOwn -11.4%
|
2025-11-03 | $273,442 | S | Form 4 |
|
ALKS
S
Alkermes plc.
Hopkinson Craig C.
• Officer • EVP R&D, Chief Medical Officer
10b5-1 SellΔOwn -10.9%
2025-10-15
$283,776
|
||||||
| ALKS |
Alkermes plc.
|
Officer • EVP R&D, Chief Medical Officer
10b5-1 SellΔOwn -10.9%
|
2025-10-15 | $283,776 | S | Form 4 |